ZYMAR

This brand name is authorized in Brazil, Canada, Mexico, Singapore, South Africa

Active ingredients

The drug ZYMAR contains one active pharmaceutical ingredient (API):

1 Gatifloxacin UNII L4618BD7KJ - GATIFLOXACIN

Gatifloxacin is an 8-methoxyfluoroquinolone with a 3-methylpiperazinyl substituent at C7. The antibacterial action of gatifloxacin results from inhibition of DNA gyrase and topoisomerase IV. The mechanism of action of fluoroquinolones including gatifloxacin is different from that of aminoglycoside, macrolide, and tetracycline antibiotics. Therefore, gatifloxacin may be active against pathogens that are resistant to these antibiotics and these antibiotics may be active against pathogens that are resistant to gatifloxacin. Read about Gatifloxacin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ZYMAR 0.3% w/v Ophthalmic solution	Health Products and Food Branch (CA)	MPI, CA: SPM

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
S01AE06		S Sensory organs → S01 Ophthalmologicals → S01A Antiinfectives → S01AE Fluoroquinolones
Discover more medicines within S01AE06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 501005901170318, 501007201176311, 501007202172318
Country: CA	Health Products and Food Branch	Identifier(s): 02257270
Country: MX	Comisión Federal para la Protección contra Riesgos Sanitarios	Identifier(s): 155M2004
Country: SG	Health Sciences Authority	Identifier(s): 12612P
Country: ZA	Health Products Regulatory Authority	Identifier(s): A39/15.1/0367